JP6975473B2 - 鼻詰まりを治療／予防するためのカルボン酸 - Google Patents

鼻詰まりを治療／予防するためのカルボン酸 Download PDF

Info

Publication number
JP6975473B2
JP6975473B2 JP2019513481A JP2019513481A JP6975473B2 JP 6975473 B2 JP6975473 B2 JP 6975473B2 JP 2019513481 A JP2019513481 A JP 2019513481A JP 2019513481 A JP2019513481 A JP 2019513481A JP 6975473 B2 JP6975473 B2 JP 6975473B2
Authority
JP
Japan
Prior art keywords
solution
nasal
nasal congestion
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019513481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516797A (ja
JP2019516797A5 (enExample
Inventor
ベッティーナ エルンスト
Original Assignee
プロポーネント バイオテック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロポーネント バイオテック ゲーエムベーハー filed Critical プロポーネント バイオテック ゲーエムベーハー
Publication of JP2019516797A publication Critical patent/JP2019516797A/ja
Publication of JP2019516797A5 publication Critical patent/JP2019516797A5/ja
Application granted granted Critical
Publication of JP6975473B2 publication Critical patent/JP6975473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019513481A 2016-05-17 2017-05-17 鼻詰まりを治療／予防するためのカルボン酸 Active JP6975473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16169882.4 2016-05-17
EP16169882 2016-05-17
PCT/EP2017/061832 WO2017198702A1 (en) 2016-05-17 2017-05-17 Carboxylic acid for treating/preventing nasal congestion

Publications (3)

Publication Number Publication Date
JP2019516797A JP2019516797A (ja) 2019-06-20
JP2019516797A5 JP2019516797A5 (enExample) 2020-06-18
JP6975473B2 true JP6975473B2 (ja) 2021-12-01

Family

ID=56014856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513481A Active JP6975473B2 (ja) 2016-05-17 2017-05-17 鼻詰まりを治療／予防するためのカルボン酸

Country Status (13)

Country Link
US (1) US20200000751A1 (enExample)
EP (1) EP3458043A1 (enExample)
JP (1) JP6975473B2 (enExample)
KR (1) KR102430892B1 (enExample)
CN (1) CN109152754A (enExample)
AU (1) AU2017266726A1 (enExample)
BR (1) BR112018072177A2 (enExample)
CA (1) CA3020485A1 (enExample)
CL (1) CL2018003270A1 (enExample)
MX (1) MX2018013475A (enExample)
RU (1) RU2018143564A (enExample)
SG (2) SG10202006016QA (enExample)
WO (1) WO2017198702A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11206245B2 (en) * 2009-10-14 2021-12-21 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
US11948678B2 (en) * 2009-10-14 2024-04-02 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
GB202004690D0 (en) * 2020-03-31 2020-05-13 Edinburgh Napier Univ Composition for enhancing immune response of cells
US12414928B2 (en) 2021-05-14 2025-09-16 Rene Dumalaog Javier Viral inactivation spray and gargling formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063363A (en) * 1997-05-27 2000-05-16 Goodwin; Gary J Treatment for upper respiratory tract infections with potassium salts
CZ301349B6 (cs) * 1997-12-23 2010-01-27 Schering Corporation Prostredek k lécbe respiracních a kožních onemocnení, který obsahuje alespon jednoho antagonistu leukotrienu a alespon jedno antihistaminikum
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
EP1671629A4 (en) * 2003-09-19 2008-11-26 Otsuka Pharma Co Ltd HUMAN BETA DEFENSIN SECRETION AMPLIFIER
US20070256812A1 (en) * 2006-04-19 2007-11-08 Wen-Chen Wei Multidirectional heat dissipating structure
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
CA2886270C (en) * 2012-10-03 2020-04-07 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders

Also Published As

Publication number Publication date
MX2018013475A (es) 2019-08-12
WO2017198702A1 (en) 2017-11-23
BR112018072177A2 (pt) 2019-02-12
CN109152754A (zh) 2019-01-04
JP2019516797A (ja) 2019-06-20
RU2018143564A3 (enExample) 2020-07-23
RU2018143564A (ru) 2020-06-17
SG11201808322PA (en) 2018-10-30
CA3020485A1 (en) 2017-11-23
CL2018003270A1 (es) 2019-02-22
SG10202006016QA (en) 2020-07-29
KR20190009294A (ko) 2019-01-28
AU2017266726A1 (en) 2018-10-11
KR102430892B1 (ko) 2022-08-09
US20200000751A1 (en) 2020-01-02
EP3458043A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
ES2263643T3 (es) Uso de hidroxietilrutosidos para el tratamiento de los sintomas del r esfriado comun, de la fiebre de heno y de infecciones relacionadas con el tacto respiratorio.
US9844580B2 (en) Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis
JP2005508314A (ja) 副鼻腔炎の治療のためのエアゾール状鬱血除去薬
JP6975473B2 (ja) 鼻詰まりを治療／予防するためのカルボン酸
EA008165B1 (ru) Композиции для лечения простуды
US9861647B2 (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US9023815B2 (en) Method for treating rhinitis and sinusitis by rhamnolipids
JP2019516797A5 (enExample)
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US20100311691A1 (en) Compositions of s-alkylisothiouronium derivatives for treating upper respiratory congestion
US20060210482A1 (en) Chemical composition and method for cold and sinus relief
US20230072392A1 (en) Nasal spray
HK40002357A (en) Carboxylic acid for treating/preventing nasal congestion
CA3169607A1 (en) Iodine compounds for treating respiratory pathogens
WO2025146443A1 (en) Antibacterial compositions comprising honey
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
AU2015204387A1 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211029

R150 Certificate of patent or registration of utility model

Ref document number: 6975473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250